Board of Directors
Gordon Sato, PhD | Co-Founder & Chairman of the Board, A&G Pharmaceutical
Dr. Sato is a world-renowned cell biologist and entrepreneur whose seminal contributions to modern cell culture and cancer biology are recognized worldwide. A pioneer in the isolation of functional cell lines and the development of serum-free hormone supplemented medium, Dr. Sato is best known for his discovery that the polypeptide factors required for the culture of mammalian cells outside the body are also important regulators of differentiated cell functions with research utility in the culture of new types of cells. He is also the co-inventor of Erbitux (cetuximab), the anti-EGFR monoclonal antibody therapy for the treatment of metastatic colorectal cancer and head and neck cancer. Dr. Sato has been instrumental in launching a number of successful biotechnology companies, including Collaborative Research, Hana Biological, Upstate Biotechnology, and A&G Pharmaceutical. He has served as Director of the W. Alton Jones Cell Science Center, a Professor of Biology at the University of California San Diego, and a scientific advisor to President Richard Nixon when the president declared the War on Cancer and enacted the National Cancer Act. Dr. Sato is Director Emeritus of the W. Alton Jones Cell Science Center, Professor Emeritus of Tsinghua University in the People’s Republic of China, an Adjunct Professor and member of the Board of Visitors at the University of Maryland School of Pharmacy, and a member of the Scientific Board of TKT Pharmaceutical. He is an elected member of the U.S. National Academy of Sciences and the American Academy of Arts & Sciences. He has authored or co-authored more than 150 publications in cell and molecular biology. The recipient of a number of international scientific awards for his research, most recently Dr. Sato was selected as a Rolex Award for Enterprise laureate for his Manzanar Project, which focuses on helping impoverished coastal communities in Eritrea develop a low-tech, sustainable agricultural economy. Supported by the GI bill, Dr. Sato received a B.S. in Biochemistry at the University of Southern California and a PhD in Biophysics at the California Institute of Technology under Nobel laureate Max Delbruek.
Lars Hanan, MBA | Co-Founder and Managing Partner, BroadOak Capital Partners
Tom Hancock | Principal, New England Partners/Nexus Medical Partners Fund
SeungSuh “Stanley” Hong, PhD | Vice President of Business Development, Celltrion
Jennie Mather, PhD | Senior Vice President, Stem Cell Research, MacroGenics
Ginette Serrero, PhD | Co-Founder and CEO
Seung Il-Shin, PhD | Founder, Celltrion
Gordon Sato, PhD | Co-Founder & Chairman of the Board, A&G Pharmaceutical
Dr. Sato is a world-renowned cell biologist and entrepreneur whose seminal contributions to modern cell culture and cancer biology are recognized worldwide. A pioneer in the isolation of functional cell lines and the development of serum-free hormone supplemented medium, Dr. Sato is best known for his discovery that the polypeptide factors required for the culture of mammalian cells outside the body are also important regulators of differentiated cell functions with research utility in the culture of new types of cells. He is also the co-inventor of Erbitux (cetuximab), the anti-EGFR monoclonal antibody therapy for the treatment of metastatic colorectal cancer and head and neck cancer. Dr. Sato has been instrumental in launching a number of successful biotechnology companies, including Collaborative Research, Hana Biological, Upstate Biotechnology, and A&G Pharmaceutical. He has served as Director of the W. Alton Jones Cell Science Center, a Professor of Biology at the University of California San Diego, and a scientific advisor to President Richard Nixon when the president declared the War on Cancer and enacted the National Cancer Act. Dr. Sato is Director Emeritus of the W. Alton Jones Cell Science Center, Professor Emeritus of Tsinghua University in the People’s Republic of China, an Adjunct Professor and member of the Board of Visitors at the University of Maryland School of Pharmacy, and a member of the Scientific Board of TKT Pharmaceutical. He is an elected member of the U.S. National Academy of Sciences and the American Academy of Arts & Sciences. He has authored or co-authored more than 150 publications in cell and molecular biology. The recipient of a number of international scientific awards for his research, most recently Dr. Sato was selected as a Rolex Award for Enterprise laureate for his Manzanar Project, which focuses on helping impoverished coastal communities in Eritrea develop a low-tech, sustainable agricultural economy. Supported by the GI bill, Dr. Sato received a B.S. in Biochemistry at the University of Southern California and a PhD in Biophysics at the California Institute of Technology under Nobel laureate Max Delbruek.
Lars Hanan, MBA | Co-Founder and Managing Partner, BroadOak Capital Partners
Tom Hancock | Principal, New England Partners/Nexus Medical Partners Fund
SeungSuh “Stanley” Hong, PhD | Vice President of Business Development, Celltrion
Jennie Mather, PhD | Senior Vice President, Stem Cell Research, MacroGenics
Ginette Serrero, PhD | Co-Founder and CEO
Seung Il-Shin, PhD | Founder, Celltrion
© 2009 A&G Pharmaceutical, Inc. All Rights Reserved. | Terms of Use | Privacy
